Companies
LanzaTech
its gas-fermentation platform converts industrial emissions and gasified waste into recycled-carbon ethanol; 2025 revenue reached 55.8 million dollars, its Kuji City (Japan) municipal-solid-waste pilot produces about 400 t/yr at one-tenth commercial scale, and LanzaTech's stake in LanzaJet rose to 53% by December 2025.
- Country
- United States
- Ticker
- LNZA
ISCC PLUS
US 45Q
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| biofuels-bioenergy | ✓ | ✓ | ✓ | ✓ |
| cdr-carbon-management | ✓ | ✓ | — | ✓ |
| foundries-design | ✓ | ✓ | — | ✓ |
| platform-chemicals | ✓ | ✓ | ✓ | ✓ |
Regulatorsepareachneafdaefsamoa-chinaademe
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | $55.8 million (2025-12-31) | ir.lanzatech.com |
| Capacity | approximately 400 tons of ethanol per year (2026-01-07) | ir.lanzatech.com · quiverquant.com |
| Funding | investment by SBR joint venture and Japanese Ministry of the Environment (2026-01-07) | ir.lanzatech.com · quiverquant.com |
| Headcount | 192 employees (2025-12-31) | cstproxy.com |
| Production site | Kuji City pilot plant, Japan | cstproxy.com · quiverquant.com |
| Regulatory approval | around 26 approvals for biocatalysts across USA, China, India, Austria, Belgium, and Japan | cstproxy.com |
| Certification | undergoing world's first ISCC EU certification pathway for recycled carbon fuels in China | sec.gov |
Independent sources: cstproxy.com · quiverquant.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biological carbon capture & utilization (bio-CCU: gas fermentation, CO2-to-protein, e-fuels) | cdr-carbon-management | Medium | → |
| Biosynthetic butanol, isobutanol and bio-C4 platforms | platform-chemicals | Medium | → |
| Biosynthetic ethylene & bio-ethylene oxide | platform-chemicals | Low | → |
| Gas fermentation to chemicals | biofuels-bioenergy | Medium | → |
| Metabolic engineering | foundries-design | Medium | → |
| Power-to-X with biological step | biofuels-bioenergy | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.